Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0275
PERSPECTIVE
|
Trastuzumab – emtansine for HER2-positive breast cancer patients and development of new therapies.giuseppe zanotti outlet
|
Prof. George Zografos, MD, PhD.
|
Affiliation:Head of the Breast Unit, Head of 1st Department of Propaedeutic Surgery, University of Athens, Greece.
Tel: +306932524836
E-mail: gzografo@med.uoa.gr |
Abstract
The trastuzumab – emtansine conjugate has been approved 5-years ago for the treatment of metastatic HER2 – positive breast cancer following treatment with chemotherapy plus trastuzumab. This significant overall survival prolongation has led to several underway phase III randomized clinical trials evaluating the efficacy of trastuzumab – emtansine as first line therapy in the metastatic over adjuvant setting.
This perspective article discusses beyond the targets of this conjugate as well as other novel therapies for effective breast cancer treatment.
(Citation: Gastric & Breast Cancer 2018; 13(1): 50-70)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
